Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System, making them eligible for Zephyr® Valve treatment. These patients experienced improvements in lung function, quality of life, and treated lobe volume reduction.
The 5-year follow-up data from the LIBERATE study demonstrated durable improvements in lung function for patients treated with Zephyr Valves, with FEV1 improvements ranging from 109 mL in Year 1 to 79 mL at Year 5. The study also showed an acceptable safety profile and a 38% mortality rate over 5 years, lower than historical medically managed control patients.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for severe lung disease, has announced its participation in the Lake Street 8th Annual Best Ideas Growth Conference. The event is scheduled to take place on Thursday, September 14, 2024, in New York.
Pulmonx representatives will be engaging in investor meetings during the conference, providing an opportunity for the company to showcase its innovations and growth strategies in the field of lung disease treatment. This participation underscores Pulmonx's commitment to engaging with investors and sharing insights about its market position and future prospects.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company will engage in a fireside chat on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This event provides an opportunity for Pulmonx to showcase its innovations and discuss its position in the healthcare industry with potential investors and analysts.
Pulmonx (Nasdaq: LUNG) reported strong financial results for Q2 2024. The company achieved record worldwide revenue of $20.8 million, a 21% increase year-over-year. U.S. revenue grew 26% to $13.9 million, while international revenue increased 12% to $6.9 million. Gross margin remained steady at 74%.
Key highlights include:
- Addition of 17 new Zephyr® Valve U.S. treatment centers
- First U.S. patients treated with AeriSeal® System in CONVERT II trial
- Net loss of $15.3 million, or $0.39 per share
- Adjusted EBITDA loss of $7.6 million
Pulmonx maintains its 2024 revenue guidance of $81-84 million and expects gross margin to be 74-75%.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management is set to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website. This conference provides an opportunity for Pulmonx to showcase its innovations and growth strategies in the field of lung disease treatments to a wider audience of investors and industry professionals.
Pulmonx, a leader in minimally invasive lung disease treatments, will release its Q2 2024 financial results on July 31, 2024. The announcement will be made post-market close, and a conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access both live and archived webcasts on Pulmonx's investor relations website.
Pulmonx announced the grant of inducement awards to Mehul Joshi, the new Chief Financial Officer, consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock. The stock option grant has an exercise price of $9.28 per share and will vest over a three-year period, while the restricted stock units will vest over four years. The awards were approved as an inducement to Mr. Joshi's employment under Nasdaq Listing Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported financial results for Q1 2024, achieving a 30% year-over-year revenue growth, recording $18.9 million in worldwide revenue, with $12.9 million in U.S. revenue. The company realized a gross margin of 75% and treated the first patient in significant clinical trials. Pulmonx appointed new executives to drive growth and expects revenue for 2024 to be in the range of $81 million to $84 million.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
